1 / 29

Pharmaceutical Shortages: Impact on Patients, Professionals and the Public

Pharmaceutical Shortages: Impact on Patients, Professionals and the Public Bernadette Belgado, Pharm.D. – UF Health at Jacksonville West Paul, M.D., Ph.D. – Wake Med Health. Drug Shortages: causes & solutions . Bernadette Belgado, Pharm.D. Director, Drug Information Center

Télécharger la présentation

Pharmaceutical Shortages: Impact on Patients, Professionals and the Public

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Pharmaceutical Shortages: Impact on Patients, Professionals and the Public Bernadette Belgado, Pharm.D. – UF Health at Jacksonville West Paul, M.D., Ph.D. – Wake Med Health

  2. Drug Shortages: causes & solutions Bernadette Belgado, Pharm.D. Director, Drug Information Center Manager, Department of Pharmacy Shands Jacksonville Department of Pharmacy Clinical Assistant Professor UF College of Pharmacy

  3. Objectives • Explain the reasons for medication shortages • Discuss drug shortage legislation • No disclosures

  4. New Drug Shortages by Year Keuhn BM. JAMA. 2013;309(6):532-533

  5. Reported reasons for sterile injectable drug shortages in 2011 Woodcock J, Wosinska M. Clin Pharmacol Ther 2013;92:170-6.

  6. Drug Supply Chain Raw materials http://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm277626.htm

  7. Raw Materials 2008 – heparin recall Over 200 patients died as a result of contaminated heparin with over-sulfated chondroitin Raw materials plant in China was never inspected by the FDA Foreign markets supply 80% of raw materials Increased quality awareness and regular inspection of foreign raw materials plants mandated by FDA

  8. This family-owned workshop in Xinwangzhuang, a village in Juangsu Province, China, processes pig intestinesfor heparin http://www.nytimes.com/2008/03/30/weekinreview/30bogdanich.html?ref=heparindrug&_r=0

  9. Drug Supply Chain http://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm277626.htm

  10. Drug Manufacturers • Generic injectable drugs (73%) • Lack of redundancy in manufacturing processes • 71% of market controlled by 3 manufacturers • Routine facility maintenance • Business decisions to discontinue drug • Unable to support demand Woodcock J, Wosinska M. Clin Pharmacol Ther 2013;92:170-6.

  11. Drug Manufacturers Lack of sterility Particulates of foreign matter Crystallization of the active ingredient Precipitates New/unintended impurities or degradation Equipment breakdown Woodcock J, Wosinska M. Clin Pharmacol Ther 2013;92:170-6

  12. Drug Supply Chain http://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm277626.htm

  13. Regulatory Issues • New FDA Commissioner in 2009 • Enforcement and regulatory activities spiked from 2009-2011 • Warning letters to pharmaceutical manufacturers regarding quality increased 42% in 2009 and up 156% in 2010. • Simultaneously shutting down 4 major generic manufacturers of generic medications • 30% of decrease in manufacturing capacity 112th Congress 2012. http://oversight.house.gov/report/fdas-contribution-to-the-drug-shortage-crisis.

  14. FDA Warning letters 2004-2011 Number of letters FDA Fiscal Year 2011 Enforcement Statistics

  15. Regulatory Issues • FDA increased enforcement of Unapproved Drugs • Drug Evaluation & Safety Initiative (DESI) • Drugs approved or deemed identical, related, or similar (IRS) between 1938 – 1962 • Pre-1938 drugs grandfathered • No change to the formulation, dosage form, potency, route of administration, indication, or intended patient population • FDA requests NDA for any unapproved drug http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070290.pdf http://www.ashp.org/DrugShortages/NotAvailable/Bulletin.aspx?id=602

  16. Regulatory Issues - MMA Medicare Modernization Act (MMA) 2003 • Changed pricing formula for reimbursement in outpatient setting • Originally average wholesale price (AWP) • Generic availability erodes selling prices by ~ 85-90% after a year • Average selling price (ASP) + 6% • MMA limits - Manufacturers only allowed to increase prices by 6% biannually Cabner BA. N Engl J Med 2011 365:2147-49

  17. 340B Pricing Program • Provides nominal pricing for outpatient medications • One-third of all hospitals are eligible for 340B prices • Unintended consequence of MMA and 340B • New manufacturers are not entering the marketplace to produce generic medications • Only 7 generic companies make sterile injectables

  18. Drug Supply Chain http://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm277626.htm

  19. Group Purchasing Organizations • GPOs – 98% of hospitals • Negotiate price and volume contracts with drug manufacturers • Six GPOs control about 90% of drugs purchased • Contract awarded on multiple factors • lowest cost, returns, rebates, stipulations for “failure to supply” • Speculation that fewer generic manufacturers are a direct result of the GPO structure Nelson R. Medscape. http://www.medscape.com/viewarticle/778146

  20. Drug Supply Chain http://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm277626.htm

  21. Health Systems • “Just in time” inventory practices • Pharmacy inventory turns short • 30 days • Hoarding and stockpiling

  22. Medicare Modernization Act Heparin recall Unapproved drugs initiative New FDA Commissioner Keuhn BM. JAMA. 2013;309(6):532-533

  23. FDA Solutions • Allow temporary importation of foreign equivalent • Propoven from UK for propofol shortage • Phenylephrine from UK • Sodium Bicarbonate from Australia • Allow affected drug with conditions – safety considered • Potassium Phosphate – double filtration required • Mannitol – heat medication to dissolve crystals • Alteplase – rubber stopper particles – filtering required

  24. FDA Safety & Innovation Act (FDASIA) • Executive presidential order – October 2011 • FDASIA – July 2012 • Requires at least 6 month notification to FDA and other manufacturers of potential shortages or ASAP • No civil or monetary penalties for industry noncompliance • FDA required to keep updated list of drugs and reasons • Expedited review of new generics

  25. Presidential Executive order Medicare Modernization Act Heparin recall Unapproved drugs initiative FDASIA New FDA Commissioner Keuhn BM. JAMA. 2013;309(6):532-533

  26. Keuhn BM. JAMA. 2013;309(6):532-533

More Related